NYSE:AIM AIM ImmunoTech (AIM) Stock Price, News & Analysis $0.33 0.00 (0.00%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$0.31▼$0.3350-Day Range$0.26▼$0.4252-Week Range$0.25▼$0.68Volume103,331 shsAverage Volume239,435 shsMarket Capitalization$16.89 millionP/E RatioN/ADividend YieldN/APrice Target$5.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrends Get AIM ImmunoTech alerts: Email Address AIM ImmunoTech MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,424.4% Upside$5.00 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews Sentiment-0.81Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.58 out of 5 starsMedical Sector847th out of 910 stocksBiological Products, Except Diagnostic Industry147th out of 155 stocks 3.5 Analyst's Opinion Consensus RatingAIM ImmunoTech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageAIM ImmunoTech has only been the subject of 1 research reports in the past 90 days.Read more about AIM ImmunoTech's stock forecast and price target. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for AIM. Previous Next 0.0 Dividend Strength Dividend YieldAIM ImmunoTech does not currently pay a dividend.Dividend GrowthAIM ImmunoTech does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AIM. Previous Next 1.2 News and Social Media Coverage News SentimentAIM ImmunoTech has a news sentiment score of -0.81. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for AIM ImmunoTech this week, compared to 1 article on an average week.Search InterestOnly 2 people have searched for AIM on MarketBeat in the last 30 days. This is a decrease of -33% compared to the previous 30 days.MarketBeat Follows2 people have added AIM ImmunoTech to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, AIM ImmunoTech insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.02% of the stock of AIM ImmunoTech is held by insiders.Percentage Held by InstitutionsOnly 12.02% of the stock of AIM ImmunoTech is held by institutions.Read more about AIM ImmunoTech's insider trading history. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of AIM ImmunoTech is -0.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of AIM ImmunoTech is -0.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAIM ImmunoTech has a P/B Ratio of 2.98. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the Markets"Doomsday indicator” flashing for the first time since the Great Depression...It's been a bloodbath in the markets. The seven most valuable US tech companies lost a combined $1 trillion - in a single day. And things could get a lot worse...Click here to discover how Wall Street insiders are quietly preparing for a market crash >>> About AIM ImmunoTech Stock (NYSE:AIM)AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente; Jubilant HollisterStier; Sterling Pharma Solutions; Erasmus University Medical Center Rotterdam; Azenova, LLC; and Alcami Corporation. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.Read More AIM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AIM Stock News HeadlinesSeptember 4 at 2:07 AM | americanbankingnews.comAIM ImmunoTech (NYSE:AIM) Price Target Cut to $5.00 by Analysts at Ascendiant Capital MarketsAugust 20, 2024 | globenewswire.comAIM ImmunoTech Announces Print Publication and Further Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer ResearchSeptember 7, 2024 | Golden Crest (Ad)Biden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security.August 17, 2024 | msn.comAIM ImmunoTech Inc. (AMEX:AIM) Q2 2024 Earnings Call TranscriptAugust 16, 2024 | finanznachrichten.deAIM ImmunoTech Inc.: AIM ImmunoTech Reports Second Quarter 2024 Financial Results and Provides Corporate UpdateAugust 16, 2024 | seekingalpha.comAIM ImmunoTech Inc. (AIM) Q2 2024 Earnings Call TranscriptAugust 16, 2024 | globenewswire.comAIM ImmunoTech Reports Second Quarter 2024 Financial Results and Provides Corporate UpdateAugust 13, 2024 | uk.finance.yahoo.comSamson Rock Capital LLP - Form 8.3 - Trident Royalties PlcSeptember 7, 2024 | Golden Crest (Ad)Biden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial independence and security.August 13, 2024 | msn.comJim Click's 2006 Ford Mustang FR500C Race Car Hits Bring a Trailer AuctionAugust 13, 2024 | msn.com535p?! This broker just hiked the forecast for the Rolls-Royce share priceAugust 13, 2024 | globenewswire.comAIM ImmunoTech to Discuss Second Quarter 2024 Financial Results on August 16, 2024, and Host Conference Call and WebcastJuly 29, 2024 | globenewswire.comAIM ImmunoTech Announces Release of the Next CEO Corner SegmentJuly 25, 2024 | finance.yahoo.comAIM Announces New Positive Data on Ampligen’s Anti-Tumor Potential When Used as Part of a Combination TherapyJuly 24, 2024 | globenewswire.comAIM Announces New Positive Data on Ampligen's Anti-Tumor Potential When Used as Part of a Combination TherapyJuly 3, 2024 | globenewswire.comAIM ImmunoTech Announces Release of the Next CEO Corner SegmentJune 10, 2024 | globenewswire.comAIM ImmunoTech to Participate in the Virtual Investor Pitch ConferenceJune 3, 2024 | globenewswire.comAIM ImmunoTech to Participate in the Virtual Investor Lunch Break SeriesSee More Headlines Receive AIM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AIM ImmunoTech and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/14/2024Today9/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNYSE:AIM CUSIPN/A CIK946644 Webaimimmuno.com Phone(352) 448-7797Fax215-988-1739Employees20Year Founded1990Price Target and Rating Average Stock Price Target$5.00 High Stock Price Target$5.00 Low Stock Price Target$5.00 Potential Upside/Downside+1,424.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.64) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-28,960,000.00 Net Margins-13,952.74% Pretax Margin-13,952.74% Return on Equity-269.04% Return on Assets-141.74% Debt Debt-to-Equity Ratio0.05 Current Ratio1.17 Quick Ratio1.17 Sales & Book Value Annual Sales$201,000.00 Price / Sales84.03 Cash FlowN/A Price / Cash FlowN/A Book Value$0.11 per share Price / Book2.98Miscellaneous Outstanding Shares51,496,000Free Float51,486,000Market Cap$16.89 million OptionableNot Optionable Beta-0.39 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesMr. Thomas K. Equels Esq. (Age 71)J.D., M.S., Executive Vice Chairman, CEO & President Comp: $953.19kMr. Robert Dickey IV (Age 68)M.B.A., Chief Financial Officer Comp: $64.48kMr. Peter W. Rodino III (Age 73)Esq., J.D., COO, Executive Director of Governmental Relations, General Counsel & Secretary Comp: $484.94kAnn Marie E. CoverlyDirector of Administration & Human Resources and Deputy Investor Relations CoordinatorDr. Carol A. Smith (Age 73)Chief Manufacturing Officer & Deputy Chief Scientific Officer Comp: $170.77kDr. Christopher McAleer Ph.D.Scientific OfficerDr. Ralph Christopher Cavalli Ph.D. (Age 66)Vice President of QC & Manufacturing Comp: $234.79kMore ExecutivesKey CompetitorsChimerixNASDAQ:CMRXOvid TherapeuticsNASDAQ:OVIDCellectar BiosciencesNASDAQ:CLRBOmega TherapeuticsNASDAQ:OMGABeyondSpringNASDAQ:BYSIView All CompetitorsInsiders & InstitutionsArmistice Capital LLCBought 4,078,000 shares on 8/15/2024Ownership: 7.919%Thomas K EquelsBought 61,729 shares on 5/6/2024Total: $25,308.89 ($0.41/share)Peter W Rodino IIIBought 30,865 shares on 5/6/2024Total: $12,654.65 ($0.41/share)Nancy BryanBought 38,462 shares on 3/21/2024Total: $15,000.18 ($0.39/share)Thomas K EquelsBought 75,758 shares on 3/15/2024Total: $25,000.14 ($0.33/share)View All Insider TransactionsView All Institutional Transactions AIM Stock Analysis - Frequently Asked Questions How have AIM shares performed this year? AIM ImmunoTech's stock was trading at $0.4399 at the beginning of the year. Since then, AIM shares have decreased by 25.4% and is now trading at $0.3280. View the best growth stocks for 2024 here. How were AIM ImmunoTech's earnings last quarter? AIM ImmunoTech Inc. (NYSE:AIM) released its earnings results on Wednesday, August, 14th. The company reported ($0.03) EPS for the quarter. The business earned $0.05 million during the quarter. AIM ImmunoTech had a negative net margin of 13,952.74% and a negative trailing twelve-month return on equity of 269.04%. When did AIM ImmunoTech's stock split? Shares of AIM ImmunoTech split on the morning of Saturday, January 1st 2000. The 12-1 split was announced on Saturday, January 1st 2000. The newly minted shares were issued to shareholders after the closing bell on Monday, August 29th 2016. An investor that had 100 shares of stock prior to the split would have 1,200 shares after the split. Who are AIM ImmunoTech's major shareholders? AIM ImmunoTech's top institutional investors include Armistice Capital LLC (7.92%). Insiders that own company stock include Thomas K Equels, Stewart Appelrouth, Peter W Rodino III and Nancy Bryan. View institutional ownership trends. How do I buy shares of AIM ImmunoTech? Shares of AIM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of AIM ImmunoTech own? Based on aggregate information from My MarketBeat watchlists, some other companies that AIM ImmunoTech investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), iBio (IBIO), Vaxart (VXRT), Tonix Pharmaceuticals (TNXP), VBI Vaccines (VBIV) and T2 Biosystems (TTOO). This page (NYSE:AIM) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredThe death of Nvidia?Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AIM ImmunoTech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AIM ImmunoTech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AIM Stock Alerts